2024
The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Krumholz H, Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Coppi A, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Al Mouslmani M, Putrino D, Carr K, Carvajal-Gonzalez S, Charnas L, De Jesus M, Ziegler F, Iwasaki A. The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID. The American Journal Of Medicine 2024 PMID: 38735354, DOI: 10.1016/j.amjmed.2024.04.030.Peer-Reviewed Original ResearchLC trialPROMIS-29Participants' homesTargeting viral persistencePlacebo-controlled trialDouble-blind studyElectronic health recordsCore Outcome MeasuresLong COVIDEQ-5D-5LRepeated measures analysisEvidence-based treatmentsPhase 2Double-blindParticipant-centred approachStudy drugPrimary endpointSecondary endpointsCommunity-dwellingHealth recordsHealthcare utilizationContiguous US statesViral persistencePatient groupDrug treatment
2017
Urban–Rural Comparisons in Hospital Admission, Treatments, and Outcomes for ST-Segment–Elevation Myocardial Infarction in China From 2001 to 2011
Li X, Murugiah K, Li J, Masoudi FA, Chan PS, Hu S, Spertus JA, Wang Y, Downing NS, Krumholz HM, Jiang L. Urban–Rural Comparisons in Hospital Admission, Treatments, and Outcomes for ST-Segment–Elevation Myocardial Infarction in China From 2001 to 2011. Circulation Cardiovascular Quality And Outcomes 2017, 10: e003905. PMID: 29158421, PMCID: PMC6312853, DOI: 10.1161/circoutcomes.117.003905.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overChinaDisease ManagementFemaleHealthcare DisparitiesHospital MortalityHospitalizationHospitals, RuralHospitals, UrbanHumansMaleMiddle AgedOdds RatioQuality ImprovementRetrospective StudiesRural PopulationST Elevation Myocardial InfarctionSurvival RateTime FactorsUrban PopulationConceptsEvidence-based treatmentsMyocardial infarctionEnzyme inhibitors/angiotensin receptor blockersRural hospitalsST-segment elevation myocardial infarctionUrban-rural disparitiesAngiotensin receptor blockersElevation myocardial infarctionAdjusted odds ratioResource-intensive careRisk-adjusted ratesHospital deathReperfusion therapyReceptor blockersHospital admissionCardiac facilitiesPatient outcomesOdds ratioCare persistUrban hospitalΒ-blockersBetter outcomesRural careHealthcare resourcesST segment
2016
Acute Myocardial Infarction in Women
Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, Lindley KJ, Vaccarino V, Wang TY, Watson KE, Wenger NK. Acute Myocardial Infarction in Women. Circulation 2016, 133: 916-947. PMID: 26811316, DOI: 10.1161/cir.0000000000000351.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionMortality rateFirst scientific statementOutcomes of womenCardiovascular disease mortalityCardiovascular disease riskCardiovascular disease mortality ratesCoronary heart diseaseAmerican Heart AssociationDisease mortality ratesEvidence-based treatmentsCause of mortalityClinical presentationPathophysiological mechanismsHeart AssociationDisease mortalityHeart diseaseCardiovascular diseaseSex-specific differencesCurrent evidenceInfarctionDisease riskWomenScientific statement